Detail akcie Aldexa Therap online

Business Summary: Aldeyra Therapeutics, Inc. is a biotechnology company focused on discovering therapies designed to treat immune-mediated and metabolic diseases. The Company's approach is to develop pharmaceuticals that modulate protein systems, instead of directly inhibiting or activating single protein targets, with the goal of optimizing multiple pathways at once while minimizing toxicity. Its product candidates include reactive aldehyde species (RASP) modulators ADX-629, ADX 248, ADX-743, ADX-631, ADX-246, and chemically related molecules for the potential treatment of systemic and retinal immune-mediated and metabolic diseases. Its late-stage product candidates are reproxalap, a RASP modulator for the potential treatment of dry eye disease and allergic conjunctivitis, and ADX-2191, a novel formulation of intravitreal methotrexate for the potential treatment of retinitis pigmentosa. ADX 629 is in Phase II clinical trials for moderate alcohol-associated hepatitis and Sjogren-Larsson Syndrome.
Financial Summary: BRIEF: For the fiscal year ended 31 December 2024, Aldeyra Therapeutics Inc revenues was not reported. Net loss increased 49% to $55.9M. Higher net loss reflects Biotechnology segment loss increase of 40% to $60.1M. Basic Earnings per Share excluding Extraordinary Items decreased from -$0.64 to -$0.94.